CEACAM5 and colorectal carcinoma: Finally, we recognized three prospective novel markers of CRC progression (CEA, IL-8 and prolactin) that hold potential to be utilised in clinical oncology, as they significantly increase with CRC progression and correlate with Dukes’ stage.